Hereditary Angioedema: Diagnosis, Management, Current State of Art and Advances

Abstract
 Hereditary angioedema (HAE) is a rare, mostly inherited disorder however 25% of patients have de novo mutations. Although it’s rarity, it can be life threatening due to laryngeal involvement. Along with understanding the basis swelling, several new treatment options aside from C1-inhibitory protein (C1-INH) replacement been developed and are avaible on markets. However avaibility approved drugs for attacks HAE varies world wide. Treatment management requires treatment, pre-procedural long term prophylaxis (LTP). C1-INH which was firstly on-demand LTP by iv route, nowadays LTP, other used orally sc route. Despite developing medications, permanent such as gene therapy needed.